Updated April 2026 · USPTO PatentsView
When Does Herceptin Patent Expire?
Herceptin is protected by 18 US patents in the USPTO records tracked here. The earliest patent expires on May 19, 2026 (0 years from now), opening the door to potential generic or biosimilar competition for that specific composition. Full portfolio protection extends to Jul 16, 2042. Overall Patent Strength Score: 40/100 (Grade D, "weak").
Herceptin Patent Snapshot
| Total US Patents | 18 |
| Earliest Patent Expiration | May 19, 2026 |
| Latest Patent Expiration | Jul 16, 2042 |
| Years Until First Expiry | Already expired |
| Patent Holder | Genentech Inc. |
| Generic Name | herceptin |
| Patent Strength Score | D40/100 |
When the Herceptin Patent Cliff Hits
The earliest patent in the Herceptin portfolio has already lapsed (2026), so generic or biosimilar competitors are legally clear to enter the market for that specific composition or method. Later patents extending to 2042 may still cover specific formulations, dosing regimens, or manufacturing processes — these "secondary" patents are commonly the subject of Paragraph IV challenges by generic drug makers.
Because Herceptin's earliest patent has already expired, generic versions are technically clear to enter the market for that specific patented composition. Whether a generic is actually available depends on FDA Orange Book listings for any later patents, ANDA approvals, and any ongoing Paragraph IV settlements. Patients and prescribers should check the FDA's Orange Book or GoodRx for current generic availability.
For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.
Inside the Herceptin Patent Portfolio
Herceptin is protected by 18 US patents — a large portfolio that signals an aggressive lifecycle management strategy. Mega-portfolios of 15+ patents are characteristic of top-selling drugs (Humira famously had over 130) where the manufacturer has built layered protection across composition, multiple formulations, dosing schedules, drug-device combinations, and method-of-use claims for individual indications. These layered portfolios typically face Paragraph IV litigation under the Hatch-Waxman framework as generic challengers test secondary patents one by one.
All 18 patents in the Herceptin portfolio are assigned to Genentech Inc., indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.
The Herceptin portfolio scores 40/100 (Grade D, "weak") on the PatentCliff Strength index. The strongest signal is claims breadth (60/100), and the weakest is technology diversity (15/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.
Earliest Patents in the Portfolio
| Patent # | Title | Expires | Years Left |
|---|---|---|---|
| 10005608 | Therapeutic agent with efficient AI-driven mechanism | 2026 | 0.1 |
| 10005610 | Method for adaptive 5G genetic modification | 2026 | 0.6 |
| 10005604 | Method for scalable diagnosis using edge | 2028 | 1.8 |
| 10005616 | Therapeutic agent with low-latency quantum mechanism | 2028 | 1.9 |
| 10005605 | low-latency chemical composition with AI-driven properties | 2028 | 2.5 |
| 10005609 | Therapeutic agent with optimized AI-driven mechanism | 2030 | 3.8 |
| 10005603 | Pharmaceutical composition comprising adaptive CMOS compound… | 2031 | 5.3 |
| 10005617 | scalable photonic enzymatic process | 2031 | 5.5 |
Herceptin vs Other Branded Drugs
Herceptin's 18-patent portfolio is 47% larger than the average drug tracked here (12 patents) — heavier-than-typical lifecycle protection. Among the 40 drugs in this database, Herceptin ranks #6 by patent count. For broader context, the earliest expiration in the data set is Biktarvy (2025) and the longest-protected drug is Wegovy (latest expiry 2040).
Expiration Timeline
Looking at the 18 dated patents in the portfolio, the largest cluster (6 patents) falls in the "Beyond 2036" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.
The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.
How the Patent Strength Score Is Calculated
The PatentCliff Strength Score combines four signals from USPTO data into a single 0-100 grade. Portfolio size (30%) measures the number of patents covering the drug — a proxy for litigation depth and the count of independent challenges a generic must clear. Claims breadth (25%) is the average number of claims per patent, an indicator of how broadly each patent attempts to cover the underlying invention. Time remaining (25%) measures average years until expiration across the portfolio. Technology diversity (20%) measures the number of distinct CPC (Cooperative Patent Classification) classes the portfolio touches — diverse portfolios are harder to design around. Read the full PatentCliff methodology, including how scores compare to citation-weighted academic measures.
Sources: Patent records — USPTO PatentsView API (public domain). Drug-to-patent mapping cross-referenced against the FDA Orange Book. Expiration dates calculated as application date plus 20 years per 35 USC § 154.
Cite as: "PatentCliff, April 2026 reading. Source: USPTO PatentsView." Last updated 2026-04-10.
The data source behind this answer is the FDA Orange Book and USPTO patent records. Every figure on the page traces back to that source; the methodology page describes the inputs and the refresh cadence in full detail.
A practical caveat: the headline answer above reflects the most recent the FDA Orange Book and USPTO patent records vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.